Related Experiment Video
Updated: Jun 18, 2026
08:17
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Chronic obstructive pulmonary disease: towards pharmacogenetics
Alice M Wood1, See Ling Tan, Robert A Stockley
1University of Birmingham, Birmingham, B15 2TT, UK.
Genome Medicine
|December 3, 2009
Summary
Chronic obstructive pulmonary disease (COPD) involves various sub-phenotypes influenced by genetics. Understanding these genetic factors and disease mechanisms can personalize COPD treatment strategies for better outcomes.
Area of Science:
- Pulmonary Medicine
- Genetics
- Pharmacology
Background:
- Chronic obstructive pulmonary disease (COPD) is a global health issue with diverse sub-phenotypes.
- Individual genetic makeup influences COPD development and treatment response.
- Current management approaches are evolving towards personalized medicine.
Purpose of the Study:
- To explore the role of genetic factors in COPD sub-phenotypes.
- To discuss how understanding COPD pathophysiology and genetics can guide individualized therapy.
- To highlight pharmacogenetics as a key area for future COPD research.
Main Methods:
- Review of current literature on COPD genetics and pathophysiology.
- Analysis of the relationship between genetic predispositions and clinical phenotypes.
- Exploration of pharmacogenetic principles in the context of COPD treatment.
Main Results:
- Genetic variations contribute to COPD sub-phenotype development.
- Genotype may predict patient response to specific COPD treatments.
- Integrating genetic and clinical data offers potential for tailored therapeutic strategies.
Conclusions:
- Personalized COPD management requires understanding both clinical and genetic profiles.
- Pharmacogenetics holds significant promise for optimizing COPD treatment.
- Future research should focus on elucidating genetic risk factors and their therapeutic implications.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...